Arcosa (ACA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Jun, 2026Executive summary
Entered into a definitive agreement to be acquired by CRH, a leading building materials provider, marking a significant milestone in the company's evolution.
Transaction expected to close in Q1 2027, subject to shareholder approval and customary closing conditions.
Operations will remain business as usual until the transaction closes, with both companies operating independently.
Anticipated benefits include enhanced growth opportunities and career development for employees as part of a larger, diversified organization.
Voting matters and shareholder proposals
Shareholders will be asked to approve the merger agreement at a special meeting.
Proxy materials, including the definitive proxy statement, will be distributed to shareholders for voting decisions.
Board of directors and corporate governance
Directors and executive officers may be deemed participants in the proxy solicitation related to the merger.
Additional information on directors’ and officers’ interests will be disclosed in the proxy statement and related SEC filings.
Latest events from Arcosa
- Stockholders to vote on $150/share all-cash acquisition by CRH, pending Q1 2027 close.ACA
Proxy filing - Revenue and profit rose, with strategic divestiture and a pending merger defining the quarter.ACA
Q2 2026 - Shareholders to vote on $150/share all-cash merger, with board and advisors supporting approval.ACA
Proxy filing - Shareholders to vote on a $150/share all-cash merger, with board unanimous support and appraisal rights.ACA
Proxy filing - Stavola acquisition accelerates infrastructure focus, margin growth, and long-term value creation.ACA
Sidoti September Small-Cap Virtual Conference - CRH’s $8.5B acquisition of Arcosa offers a 25% premium and accelerates infrastructure growth.ACA
Proxy filing - Arcosa to be acquired by CRH for $8.5B, with shareholders receiving $150 per share.ACA
Proxy filing - Agreement reached for $8.5B acquisition by CRH, pending shareholder approval.ACA
Proxy filing - Adjusted EBITDA up 26% and margin expands, with 2025 guidance reaffirmed amid resilient markets.ACA
Q1 2025